Corcept Therapeutics Incorporated $(CORT)$ has announced the presentation of data from the treatment phase of its CATALYST trial at the American Diabetes Association's 85th Scientific Sessions, with simultaneous publication in Diabetes Care. The trial, assessing the effects of the cortisol modulator Korlym® in patients with hypercortisolism and difficult-to-control type 2 diabetes, demonstrated significant improvements in glucose control, body weight, and waist circumference, while reducing the need for glucose-lowering medications. The CATALYST trial, which is the largest and most rigorous to date for this purpose, initially identified hypercortisolism in 24% of the 1,057 patients screened. The treatment phase involved 136 patients randomized to receive either Korlym or a placebo over 24 weeks. Results from this phase have already been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.